These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. van Groeningen CJ; Pinedo HM; Heddes J; Kok RM; de Jong AP; Wattel E; Peters GJ; Lankelma J Cancer Res; 1988 Dec; 48(23):6956-61. PubMed ID: 3180104 [TBL] [Abstract][Full Text] [Related]
44. Evaluation of 5-FU plasma concentration by 13C breath test in patients treated with oral 5-FU analogs. Higashida M; Matsumoto H; Kubota H; Murakami H; Kawabe Y; Nakashima H; Oka Y; Okumura H; Nakamura M; Hirai T Anticancer Res; 2012 Dec; 32(12):5407-14. PubMed ID: 23225444 [TBL] [Abstract][Full Text] [Related]
45. Influence of the administration of amifostine on the pharmacokinetics of 5-fluorouracil in patients with metastatic colorectal carcinoma. Martens-Lobenhoffer J; Fuhlroth J; Ridwelski K Int J Clin Pharmacol Ther; 2000 Jan; 38(1):41-4. PubMed ID: 10667836 [TBL] [Abstract][Full Text] [Related]
46. Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer. Tamura T; Kuwahara A; Kadoyama K; Yamamori M; Nishiguchi K; Inokuma T; Takemoto Y; Chayahara N; Okuno T; Miki I; Fujishima Y; Sakaeda T Int J Med Sci; 2011; 8(5):406-12. PubMed ID: 21750645 [TBL] [Abstract][Full Text] [Related]
47. 5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients. Müller M; Mader RM; Steiner B; Steger GG; Jansen B; Gnant M; Helbich T; Jakesz R; Eichler HG; Blochl-Daum B Cancer Res; 1997 Jul; 57(13):2598-601. PubMed ID: 9205062 [TBL] [Abstract][Full Text] [Related]
48. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. Harte RJ; Matthews JC; O'Reilly SM; Tilsley DW; Osman S; Brown G; Luthra SJ; Brady F; Jones T; Price PM J Clin Oncol; 1999 May; 17(5):1580-8. PubMed ID: 10334547 [TBL] [Abstract][Full Text] [Related]
49. Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. Beumer JH; Boisdron-Celle M; Clarke W; Courtney JB; Egorin MJ; Gamelin E; Harney RL; Hammett-Stabler C; Lepp S; Li Y; Lundell GD; McMillin G; Milano G; Salamone SJ Ther Drug Monit; 2009 Dec; 31(6):688-94. PubMed ID: 19935361 [TBL] [Abstract][Full Text] [Related]
50. Plasma, whole blood and red blood cell kinetics of chloroquine after oral and parenteral administration in rabbits. Salako LA; Adelusi SA Arch Int Pharmacodyn Ther; 1983 Jan; 261(1):4-15. PubMed ID: 6847316 [TBL] [Abstract][Full Text] [Related]
51. Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients. van Kuilenburg AB; Maring JG Pharmacogenomics; 2013 May; 14(7):799-811. PubMed ID: 23651027 [TBL] [Abstract][Full Text] [Related]
52. High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion. Takimoto CH; Yee LK; Venzon DJ; Schuler B; Grollman F; Chabuk C; Hamilton JM; Chen AP; Allegra CJ; Grem JL Clin Cancer Res; 1999 Jun; 5(6):1347-52. PubMed ID: 10389918 [TBL] [Abstract][Full Text] [Related]
54. Preparation and passive target of 5-fluorouracil solid lipid nanoparticles. Du B; Yan Y; Li Y; Wang S; Zhang Z Pharm Dev Technol; 2010; 15(4):346-53. PubMed ID: 19769532 [TBL] [Abstract][Full Text] [Related]
55. [Modeling 5-FU clearance during a chronomodulated infusion]. Kwiatkowski F; Chevalier V; Chevrier R; Richard D; Cure H; Chollet P Pathol Biol (Paris); 2003 Jun; 51(4):231-3. PubMed ID: 12852999 [TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics of 5-fluorouracil and cyclophosphamide in depression rats. Duan JJ; Zhou T; Chen X; Wang Y; Wen YG; Xu F Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):427-36. PubMed ID: 22696869 [TBL] [Abstract][Full Text] [Related]
57. Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. Casale F; Canaparo R; Serpe L; Muntoni E; Pepa CD; Costa M; Mairone L; Zara GP; Fornari G; Eandi M Pharmacol Res; 2004 Aug; 50(2):173-9. PubMed ID: 15177306 [TBL] [Abstract][Full Text] [Related]
58. Clinical impact of intesified 5-Fluorouracil-based chemotherapy using a prospective pharmacokinetically-guided dosing approach: comparative study in elderly and non-elderly patients with metastatic colorectal cancer. Duffour J; Roca L; Bressolle F; Abderrahim AG; Poujol S; Pinguet F; Ychou M J Chemother; 2010 Jun; 22(3):179-85. PubMed ID: 20566423 [TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics of bolus 5-fluorouracil: relationship between dose, plasma concentrations, area-under-the-curve and toxicity. Codacci-Pisanelli G; Pinedo HM; Lankelma J; Van Groeningen CJ; Van Kuilenburg AB; Van Gennip AH; Peters GJ J Chemother; 2005 Jun; 17(3):315-20. PubMed ID: 16038526 [TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetic evaluation of pancreatic arterial infusion chemotherapy after unification of the blood supply in an animal model. Tanaka T; Yamamoto K; Sho M; Nishiofuku H; Inoue M; Sueyoshi S; Anai H; Sakaguchi H; Nakajima Y; Kichikawa K J Vasc Interv Radiol; 2010 Jan; 21(1):116-21. PubMed ID: 20123197 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]